Trials / Completed
CompletedNCT00132119
Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 233 (actual)
- Sponsor
- Somaxon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.
Detailed description
Randomized, double-blind, placebo-controlled, parallel-group, multi-centered, outpatient study to assess the efficacy, safety and tolerability of two doses of nalmefene in patients with current diagnosis of pathological gambling.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nalmefene HCl | Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks. |
| OTHER | Placebo | Placebo tablet |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-08-19
- Last updated
- 2008-05-19
Source: ClinicalTrials.gov record NCT00132119. Inclusion in this directory is not an endorsement.